Literature DB >> 25991572

Tissue Doppler Imaging as a Predictor of Immunoglobulin Resistance in Kawasaki Disease.

Daniel Phadke1, Sonali S Patel2, Samuel R Dominguez3, Heather Heizer3, Marsha S Anderson3, Mary P Glode3, Pei-Ni Jone4.   

Abstract

Kawasaki disease (KD) is characterized by myocarditis and left ventricular dysfunction during the acute phase of the illness. Despite treatment with intravenous immunoglobulin (IVIG), a significant number of patients are IVIG resistant. We evaluated KD patients in the acute phase of illness using tissue Doppler imaging (TDI) to assess whether myocardial dysfunction may predict IVIG resistance. All patients with acute KD presenting to Children's Hospital Colorado from February 2007 through March 2014 were included in this study and underwent echocardiograms with TDI evaluation at diagnosis. Patients were divided into two groups: IVIG resistant and IVIG responder. Group differences were assessed using Wilcoxon-Mann-Whitney and Chi-square testing. Receiver operating characteristic (ROC) curve analysis was utilized to determine threshold values of TDI measurements associated with IVIG resistance. Fifty-one age-matched IVIG resistant patients were compared to 51 IVIG responder patients [median age, IQR 44.57 (20.13-77.07) vs. 33.49 (17.30-62.89) months, p < 0.44]. There were significant differences in the septal and mitral early diastolic velocities (E') (p < 0.001 and p < 0.01), respectively. ROC analysis demonstrated that tricuspid E' <0.15 cm/s, septal E' <0.12 cm/s, and mitral E' <0.16 cm/s were good predictors of IVIG unresponsiveness (AUC = 0.66, 0.66, and 0.70, respectively). There were no differences between the systolic velocities and late diastolic velocities (A'). IVIG resistant KD patients present with significantly greater diastolic dysfunction compared to responders in patients with KD. TDI may be a useful tool to differentiate KD patients at higher risk of IVIG resistance.

Entities:  

Keywords:  Coronary artery lesion; Diastolic dysfunction; IVIG resistance; Kawasaki disease; Myocarditis; Tissue Doppler imaging

Mesh:

Substances:

Year:  2015        PMID: 25991572     DOI: 10.1007/s00246-015-1206-5

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  29 in total

1.  Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin.

Authors:  A M Moran; J W Newburger; S P Sanders; I A Parness; P J Spevak; J C Burns; S D Colan
Journal:  Am Heart J       Date:  2000-02       Impact factor: 4.749

2.  Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia.

Authors:  Lori B Daniels; Matthew S Tjajadi; Hannah H Walford; Susan Jimenez-Fernandez; Vera Trofimenko; Daryl B Fick; Hoang-Anh L Phan; Peter E Linz; Keshav Nayak; Andrew M Kahn; Jane C Burns; John B Gordon
Journal:  Circulation       Date:  2012-05-17       Impact factor: 29.690

3.  Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.

Authors:  Hiromi Muta; Masahiro Ishii; Jun Furui; Yosikazu Nakamura; Toyojiro Matsuishi
Journal:  Acta Paediatr       Date:  2006-02       Impact factor: 2.299

4.  Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999-2002.

Authors:  Hiroshi Yanagawa; Yosikazu Nakamura; Mayumi Yashiro; Ritei Uehara; Izumi Oki; Kazunori Kayaba
Journal:  Pediatr Int       Date:  2006-08       Impact factor: 1.524

5.  Long-term echocardiographic evaluation of cardiac size and function in patients with Kawasaki disease.

Authors:  T M Anderson; R A Meyer; S Kaplan
Journal:  Am Heart J       Date:  1985-07       Impact factor: 4.749

6.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

7.  Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease.

Authors:  S Kurotobi; N Kawakami; K Shimizu; H Aoki; S Nasuno; K Takahashi; S Kogaki; K Ozono
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

Review 8.  Kawasaki disease: late cardiovascular sequelae.

Authors:  Lori B Daniels; John B Gordon; Jane C Burns
Journal:  Curr Opin Cardiol       Date:  2012-11       Impact factor: 2.161

9.  Diastolic function in children with Kawasaki disease.

Authors:  Elif Seda Selamet Tierney; Jane W Newburger; Dionne Graham; Annette Baker; David R Fulton; Steven D Colan
Journal:  Int J Cardiol       Date:  2009-11-28       Impact factor: 4.164

10.  Cardiac biopsy of Kawasaki disease.

Authors:  C Yutani; S Go; T Kamiya; O Hirose; H Misawa; H Maeda; T Kozuka; S Onishi
Journal:  Arch Pathol Lab Med       Date:  1981-09       Impact factor: 5.534

View more
  4 in total

1.  Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.

Authors:  Eisuke Suganuma; Fumio Niimura; Shinichi Matsuda; Toshiko Ukawa; Hideaki Nakamura; Kaori Sekine; Masahiko Kato; Yuji Aiba; Yasuhiro Koga; Kuniyoshi Hayashi; Osamu Takahashi; Hiroyuki Mochizuki
Journal:  Pediatr Res       Date:  2016-12-20       Impact factor: 3.756

Review 2.  Imaging Evaluation of Kawasaki Disease.

Authors:  Pei-Ni Jone; Jennifer Romanowicz; Lorna Browne; LaDonna J Malone
Journal:  Curr Cardiol Rep       Date:  2022-08-20       Impact factor: 3.955

3.  Sequential Changes in Left Ventricular Systolic Myocardial Deformation Mechanics in Children with Recurrent Kawasaki Disease.

Authors:  Soo Jung Kang; Bo Kyeong Jin; Seo Jung Hwang; Hyo Jin Kim
Journal:  J Cardiovasc Imaging       Date:  2018-08-30

4.  Evaluation of left ventricular function in immunoglobulin-resistant children with Kawasaki disease: a two-dimensional speckle tracking echocardiography study.

Authors:  Haiyong Wang; Jing Shang; Minghui Tong; Yan Song; Litao Ruan
Journal:  Clin Cardiol       Date:  2019-06-07       Impact factor: 2.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.